The Milan-headquartered firm posted third-quarter revenue of €575 million (approximately $621 million USD), marking a 2.1% increase compared to the same period last year. A more telling indicator of underlying business health, organic growth, which strips out the effects of acquisitions, currency fluctuations, and specific business divestitures, reached an impressive 3.6%. For the first nine months of 2026, Amplifon’s revenue climbed to €1.76 billion (around $1.90 billion USD), accompanied by enhanced adjusted operating profits and robust cash generation, underscoring a period of strategic consolidation and operational optimization.
Amplifon attributes this positive performance to several interconnected factors: resilient demand for hearing care services across its principal markets, ongoing success in its "Fit4Growth" initiative designed to streamline global operations, and a relentless focus on improving efficiency and profitability. This strategic trajectory is particularly significant as the company stands on the cusp of a major vertical integration, a move that could set a new benchmark for the hearing healthcare industry.
Strong Demand and Regional Growth Fuel Performance
The third quarter saw Amplifon achieve organic growth across all three of its primary geographic segments: Europe, the Americas, and Asia Pacific. This broad-based growth reflects a global acknowledgment of the importance of hearing health and the increasing accessibility of advanced hearing solutions.
In the crucial United States market, Amplifon observed sustained strong demand within the private hearing care segment, particularly from consumers directly purchasing hearing aids and associated services. This vigor helped to counterbalance persistent softness in the insurance-funded sector, a dynamic that has influenced various parts of the healthcare industry. Across the broader Americas region, the company reported organic growth of 3.3% for the quarter. Amplifon further solidified its U.S. footprint through the strategic acquisition of 40 clinics in Louisiana, expanding its directly operated Miracle-Ear network to approximately 450 locations, demonstrating a commitment to direct consumer engagement and market penetration.
Europe, the Middle East, and Africa (EMEA) collectively recorded a 3.5% organic growth, propelled by robust performance in Southern European markets, where demographic trends and increasing awareness continue to drive demand. The Asia Pacific region exhibited the strongest organic growth, reaching 4.2%, with notable contributions from Australia and the rapidly expanding Chinese market. This geographic diversification underscores Amplifon’s global leadership and its ability to adapt to varying market dynamics.
While the overall reported revenue growth appeared relatively modest, the underlying improvements in profitability were substantial. This divergence highlights the strategic shift within Amplifon, prioritizing higher-margin operations and a more efficient retail network over sheer top-line expansion, a direct result of its ongoing operational restructuring.
Fit4Growth Initiative Delivers Enhanced Profitability
A cornerstone of Amplifon’s recent success has been its company-wide "Fit4Growth" initiative. Launched with the overarching goal of optimizing operational efficiency and strategically reallocating resources towards the most profitable facets of its business, the program has involved difficult but decisive actions. Since its inception, the initiative has led to the closure of over 230 underperforming clinics globally, the termination of a specific managed care agreement in the United States, and the divestment of non-core or underperforming businesses in the United Kingdom and India.
These strategic adjustments, while impacting overall reported revenue growth in the short term, have been instrumental in significantly enhancing Amplifon’s operating margins and overall profitability. For the first nine months of 2026, adjusted operating profit surged by 11.5% compared to the prior year. The third quarter alone witnessed an even more pronounced increase, with adjusted operating profit climbing by nearly 22%. This marked improvement in profitability, coupled with a substantial enhancement in cash generation, provides Amplifon with critical financial flexibility as it gears up for its ambitious next phase of expansion and integration with GN Hearing.
The Fit4Growth program reflects a mature strategic approach in a dynamic market. Rather than merely chasing market share, Amplifon is focused on sustainable, profitable growth, ensuring its retail network is lean, efficient, and capable of delivering premium services. This foundational strength is crucial as the company prepares to integrate a major manufacturing arm, requiring robust internal systems and financial stability.
GN Hearing Acquisition: A Pivotal Industry Transformation
Beyond its strong quarterly financial performance, Amplifon’s strategic focus remains firmly on the impending acquisition of GN Hearing, a transaction that represents a paradigm shift for both companies and the broader hearing healthcare industry. Announced earlier in the year, the deal is set to unite Amplifon’s expansive global hearing care retail network, spanning 24 countries with nearly 9,700 locations, with GN Hearing’s renowned capabilities in hearing technology research, development, and manufacturing.
The transaction, initially valued at approximately $2.5 billion USD (based on the announcement), aims to create a vertically integrated powerhouse capable of influencing the entire value chain of hearing healthcare, from product innovation to direct consumer delivery. This strategic move is not merely an expansion but a fundamental redefinition of Amplifon’s business model.
Chronology of a Landmark Deal:
- Early 2026: Amplifon announces its planned acquisition of GN Hearing from GN Store Nord, signaling a major consolidation in the sector. The proposed deal involves a significant equity component.
- June 2026: Amplifon secures a substantial €1.35 billion (approximately $1.46 billion USD) loan agreement to help finance the cash component of the acquisition, demonstrating financial readiness and market confidence in the deal.
- October 29, 2026: Amplifon shareholders convene and formally approve the necessary capital increase, which includes the proposed issuance of 56 million new Amplifon shares to GN Store Nord. This issuance would grant GN Store Nord a substantial ownership stake in the combined Amplifon entity, aligning their long-term interests and marking a critical milestone towards the transaction’s completion.
- Late 2026 (Expected): The acquisition is slated for closing by the end of 2026, contingent upon obtaining all necessary regulatory approvals and the successful separation of GN Hearing from its parent, GN Store Nord.
The strategic rationale behind this acquisition is compelling. It would bring together a portfolio of established and innovative hearing aid brands, including ReSound, Beltone, Interton, Danavox, and Danalogic, under the same organizational umbrella as one of the world’s largest and most experienced hearing care retail networks. This integration promises potential synergies across research and development, supply chain management, marketing, and direct consumer engagement.
Amplifon CEO Enrico Vita underscored the dual focus of the company’s recent efforts: strengthening existing operations while meticulously preparing for the integration. "Third quarter results confirm the solid improvement in our performance, with a very positive organic growth and a significant increase in profitability, supported by operating leverage and the Fit4Growth program," Vita stated, highlighting the foundational strength the company is building. He further emphasized the advanced planning for the integration: "Meanwhile, the planning for the integration of GN Hearing is progressing according to timetable, with the aim of being fully prepared at the closing of the acquisition. We are excited about the extraordinary opportunities for growth, innovation and value creation for all stakeholders that this new phase of our journey will bring."
This proactive approach to integration planning aims to ensure a seamless transition and rapid realization of expected synergies once the deal closes, minimizing disruption and maximizing value creation.
Broader Implications for the Hearing Healthcare Industry
The acquisition of GN Hearing by Amplifon is more than just a corporate transaction; it represents a significant structural shift in the global hearing healthcare industry. The move towards vertical integration, where a major retailer acquires a major manufacturer, has several profound implications:
- Industry Consolidation: This deal further accelerates the trend of consolidation within the hearing aid market. The industry has traditionally been dominated by a few large manufacturers (Sonova, Demant, WS Audiology, GN, Starkey) and a fragmented retail landscape. Amplifon’s move blurs the lines between these segments.
- Supply Chain Control and Innovation: For Amplifon, acquiring GN Hearing means gaining greater control over its product supply chain, potentially leading to better pricing, more tailored product development, and faster market introduction of new technologies. It could also foster a more direct feedback loop between retail insights and R&D.
- Competitive Dynamics: Competitors, both manufacturers and retailers, will be watching closely. Other independent retailers who currently stock GN Hearing brands (ReSound, Beltone) might need to reassess their sourcing strategies. Competing manufacturers might explore similar vertical integration strategies or strengthen alliances with other retail channels.
- Market Power and Pricing: A combined entity with significant presence in both manufacturing and retail could exert considerable market influence. While potentially leading to efficiencies and cost savings that could benefit consumers, it also raises questions about competition and pricing strategies in the long term. Regulatory bodies, particularly competition authorities, will scrutinize these aspects.
- Consumer Experience: The vision articulated by Amplifon is one of an enhanced, integrated consumer experience, where innovative products are seamlessly matched with expert care. This could lead to more personalized solutions and a more consistent service delivery model. However, concerns about reduced choice from a wider array of manufacturers for consumers in Amplifon’s network might also arise.
- The Role of GN Store Nord: The deal also reconfigures GN Store Nord, which will remain focused on its audio division (Jabra), a leader in intelligent audio solutions. The significant stake in Amplifon aligns GN Store Nord with the success of the combined hearing care entity, creating a new dynamic for its investment portfolio.
Market Outlook and Future Projections
Looking ahead, Amplifon has reaffirmed its expectations for the remainder of 2026, projecting organic revenue growth to exceed 3% and anticipating continued improvement in profitability. This outlook is supported by a generally positive forecast for the global hearing care market, which Amplifon expects to grow by approximately 3% this year. This growth is driven by fundamental demographic shifts, particularly an aging global population, coupled with increasing public awareness of hearing health and the continuous advancement of hearing aid technology, making devices more discreet, effective, and feature-rich.
For hearing healthcare professionals, industry analysts, and consumers alike, Amplifon’s robust performance and the impending GN Hearing acquisition paint a picture of a company strategically strengthening its core retail operations while embarking on a potentially revolutionary shift in its business model. If successfully completed and integrated, the merger would create an unprecedented entity spanning multiple critical stages of hearing healthcare delivery – from the genesis of technology in R&D labs to the final fitting and ongoing care provided in clinics worldwide. This could usher in a new era of innovation and integrated care, setting a formidable new standard for the industry.
About Amplifon
Amplifon stands as the global leader in the hearing care retail market, dedicated to empowering individuals to rediscover the richness of sound. With approximately 14,300 employees worldwide, Amplifon’s mission is to understand the unique needs of every customer, delivering exclusive, innovative, and highly personalized products and services to ensure optimal solutions and an outstanding experience. The Group, reporting annual revenues of €2.4 billion, operates through an extensive network of 9,700 locations across 24 countries and 5 continents, embodying its commitment to global reach and localized care.
About GN Store Nord and GN Hearing
GN Store Nord is a global leader in intelligent audio solutions. Through its GN Hearing division, it has been a pioneer in hearing innovation for over 150 years, developing and manufacturing advanced hearing aids under brands like ReSound, Beltone, Interton, and Danavox. Its Jabra division is renowned for its professional and consumer audio solutions. The planned divestiture of GN Hearing to Amplifon represents a strategic streamlining for GN Store Nord to focus on its core audio and intelligent communication businesses, while maintaining a significant stake in the future of integrated hearing care through its ownership in Amplifon.
Source: Amplifon and corporate disclosures.
